LimmaTech Biologics
PrivateLast Round
Grant
Feb 17, 2025
Total Funding Raised
$51.87M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
LimmaTech Biologics operates in Healthcare & Life Sciences and is based in Schlieren. Its latest recorded funding round was a Grant round in February 2025.
LimmaTech Biologics is a biopharmaceutical company that specializes in the research, development, and production of innovative bioconjugate vaccines to prevent life-threatening diseases caused by antimicrobial-resistant pathogens.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
LimmaTech Biologics Comparables
Compare LimmaTech Biologics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Omniose | 87% | |
| EveliQure Biotechnologies | 77% | |
| Inventprise | 76% |
For institutional investors. Book with your work email.
LimmaTech Biologics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Feb 17, 2025 | ||||
| Grant | Feb 27, 2024 | ||||
| Series A Extension | Feb 1, 2024 | ||||
| Series A | Oct 9, 2023 | ||||
| Seed | Oct 1, 2017 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
LimmaTech Biologics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| CARB-X | Grant |
| AXA IM Alts | Series A Extension, Series A |
| Novo Holdings | Series A |
| BNP Paribas Asset Management | Series A |
| AXA Investment Managers | Series A |
| Adjuvant Capital | Series A Extension, Series A |
| Tenmile | Series A, Series A Extension |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors grew 524% MoM, reaching 6.5K.
- Jun 23, 2026
Monthly visitors grew 74% MoM, reaching 1K.
For institutional investors. Book with your work email.
LimmaTech Biologics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about LimmaTech Biologics's valuation, stock price, and market status.
Is LimmaTech Biologics a public or private company?
LimmaTech Biologics is a private company.
What is the current stock price of LimmaTech Biologics?
LimmaTech Biologics is a private company, so its shares have no public market price. Caplight tracks LimmaTech Biologics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is LimmaTech Biologics worth (valuation)?
Valuation information for LimmaTech Biologics is not publicly available.
Can I buy LimmaTech Biologics stock?
LimmaTech Biologics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was LimmaTech Biologics's last funding round?
LimmaTech Biologics's most recent funding round was Grant on February 17, 2025.
Who are the main investors in LimmaTech Biologics?
Key investors in LimmaTech Biologics include AXA IM Alts, Novo Holdings, BNP Paribas Asset Management, AXA Investment Managers, Adjuvant Capital.
Will LimmaTech Biologics IPO soon?
No public IPO plans have been announced for LimmaTech Biologics.
How can I track LimmaTech Biologics secondary market activity?
Caplight tracks bids, offers, and trades in LimmaTech Biologics's shares on secondary markets.